52,448) for MTX, U$ 93,992 (89,366Ϫ98,982) for abatacept, and $73,100 (68,539Ϫ 81,877) for infliximab. The total QALYs gained(discounted) by MTX, abatacept, and infliximab during the same period were: 2.96 (2.89Ϫ3.03), 4.05 (3.85Ϫ4.30) and 3.26 (3.16Ϫ3.39) respectively. The Incremental Cost-Effectiveness Ratio was U$ 39,980 (36,649Ϫ45,011) for Abatacept compared to MTX compared to U$ 77,790 (62,369Ϫ98,124) per QALY gained with infliximab. CONCLUSIONS: The use of abatacept is more costϪeffective than the use of infliximab, both compared to MTX, in patients with Rheumatoid Arthritis with IR MTX in Venezuela. OBJECTIVES: Rheumatoid Arthrtis (RA) critically impair the quality of life of patients. Biologic treatments represent a therapeutic alternative for patients who failed disease-modifying antirheumatic drugs. However, their high cost is a challenge for clinicians and decision makers. The aim of this study was to assess the cost-effectiveness of biologic alternatives to treat RA currently available in Mexico, from an institutional perspective. METHODS: A decision-tree model was developed to simulate the clinical course of patients treated with etanercept (reference treatment), adalimumab, infliximab, tocilizumab or rituximab as first-line therapies, as well as associated costs over one-year period. Therapy continuation or treatment switch was evaluated at month 6. Effectiveness measures were: proportion of patients achieving 70% improvement in both, tender or swollen joint counts following the American College of Rheumatology (ACR70) criteria and quality adjusted life years gained (QALY=s .53], respectively. Etanercept is both, the less costly and the most effective alternative: US$31,504.80 less than tocilizumab (the most costly alternative) and 19.3% more patients meet the ACR70 criteria regarding rituximab (the less effective alternative). Acceptability curves showed that etanercept regardless willingness to pay would be the most cost-effective biologic. CONCLUSIONS: Due to their lower costs and favorable effectiveness profile, etanercept is dominant over other biologic treatments in the management of RA at IMSS. 
OBJECTIVES:
Inappropriate analgesia in postoperative pain (POP) raises hospitalization costs and increases the burden of several surgeries with a meaningful impact over patient's quality of life. The objective of this study was to develop an economic analysis to evaluate parecoxib, ketorolac and morphine in the treatment of POP in patients who underwent total hip arthroplasty from an institutional perspective. METHODS: A cost-effectiveness analysis was developed using a Bayesian decision-tree model, to simulate costs and effectiveness outcomes over the postoperative hospitalization period (15 days). Comparators were multimodal analgesics: morphine (52 mg/day) plus parecoxib (40 mg/day); morphine (52 mg/ day) plus ketorolac (90 mg/day) and morphine (57 mg/day) alone. Effectiveness measures were: percentage of treatment response without adverse events (AE) meeting the highest score of the patient's global evaluation survey (excellent). Effectiveness data and transition probabilities were collected from international published literature. Resource use and cost data was gathered from hospital records of patients undergoing total hip arthroplasty at the Social Security Mexican Institute (IMSS) (nϭ89). The model was calibrated according to international pharmacoeconomics guidelines. One-way and probabilistic sensitivity analyses were performed with Monte Carlo Simulation second-order approach. RESULTS: Patients who received parecoxib exhibited 41% of treatment response, followed by morphine (26%) and ketorolac (24%). Estimated costs per patient were lower with parecoxib (US$ 5,439.30) followed by ketorolac (US$5,538.91) and morphine (US$5, 553.71) . No statistical differences were found among the costs of analgesic therapies (pϾ0.05). Parecoxib showed a weak dominance against its competitors. Acceptability curves showed parecoxib as the most cost-effective therapy with 95% when willingness to pay is US$6,500. CONCLUSIONS: Results show that at the IMSS, parecoxib is a cost-effective treatment that significantly reduces POP in patients who underwent total hip arthropasty. This information could be useful for developing markets healthcare institutions in order to establish efficient analgesics improving current health outcomes. 
PMS24 THE COST EFFECTIVENESS OF STRONTIUM RANELATE VERSUS RISEDRONATE, RALOXIFENE, IBANDRONATE, ALENDRONATE AND CALCITONIN IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN IN TURKEY

OBJECTIVES:
The goal of this study was to estimate the cost-effectiveness of strontium ranelate in the treatment of postmenopausal osteoporotic women in Turkey.
METHODS:
A validated Markov microsimulation model with a Turkish payer's perspective estimated the cost per quality-adjusted life-year (QALY) of strontium ranelate treatment compared with risedronate, raloxifene, ibandronate, alendronate and calcitonin. Markov Model was used and applied in the Treeage Pro software over a cohort of 1000 patients in the pharmacoeconomical analysis. As for the sensitivity analysis, the Monte Carlo Simulation was used, applying a simulation of 10.000. Data on the effect of both treatments on fracture risk were taken from the literature. The cost of the treatments were calculated based on Turkish reimbursement systems, the indirect and intangible costs were omitted. The direct disease costs include the amount spent for the costs associated with the outpatient, inpatient, medical supplies, all the laboratory or imaging tests and the interventions performed. The costs of the side effects were added to all the drug costs. The official product summaries were used for detecting the side effects of the products. RESULTS: Strontium Ranelate provides the highest gain of quality life years and is the superlative therapeutical choice with respect to QALY. According to it's cost and effectiveness value, strontium ranelate was dominant (i.e. more effective and less costly) versus ibandronate and calcitonine for postmenopausal osteoporotic women. The cost per QALY gained by strontium ranelate compared to ibandronate was € 5582 and calcitonine was € 3943. Compared to alendronate, risedronate and raloxifene, strontium ranelate was cost effective (i.e. more costly but more effective). CONCLUSIONS: The results of this study suggest that strontium ranelate is a cost-effective strategy, in a Turkish setting, for the treatment of postmenopausal osteoporotic women. 
PMS25 COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA
OBJECTIVES:
Determine the costϪeffectiveness of abatacept or infliximab in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate (IRϪMTX) in Colombia. METHODS: Dynamic simulation techniques from a previously validated model and clinical data from published literature were used for the analysis. The functional disability was assessed using the Health Assessment Questionnaire (HAQ). A HAQ score was randomly assigned preϪtreatment based on the prevalence of the disease and the demographic characteristics for Colombia, then projected over time using the efficacy results from published trials. Direct medical costs were calculated from private and public hospitals,and the information system of the Ministry of Social Protection (SISMED) and validated with local experts (Exchange rate: $1,920 Colombian pesoϭ1 US Dollar). A 10Ϫyear time horizon and the payer's perspective were assumed. Costs and health outcomes were discounted at 3% annually. Univariate and probabilistic sensitivity analyses were performed to assess the robustness of the results of the model. RESULTS: In a hypothetical cohort of 1,000 patients with RA Ϫ IR MTX, the costs of treatmentfor the first year for MTX were U$794 dollars, compared to U$16,659 for abatacept and U$17,531 for infliximab, assuming dosages for average patients below 60 kg. Additional analysis with patients over 60 kg were included in the sensitivity analysis. After 10 years of followϪup the discounted total direct medical costs per patient were U$55,998 (54,354Ϫ57,776) for MTX, U$99,888 (94,694Ϫ104,437) for abatacept, and $79,174 (75,795Ϫ83,899)for infliximab. The total number of QALYs gained (discounted) by MTX, abatacept, and infliximab were: 2.88 (2.79Ϫ2.95), 3.94 (3.79Ϫ4.09) and 3.17 (3.09Ϫ3.27) respectively. The calculated ICERs for abatacept and infliximab compared to MTX were U$ 37,513 (35,221Ϫ39,909) and U$75,873 (62,825Ϫ103,132) per QALY gained, respectively. CONCLUSIONS: In patients with RA Ϫ IR MTX in Colombia, the use of abatacept is more cost-effective than the use of infliximab, both compared to MTX. 
PMS26 COST-EFFECTIVENESS MODELING IN OSTEOPOROSIS: A SYSTEMATIC LITERATURE REVIEW AND OVERVIEW
OBJECTIVES:
To conduct a structured review of the recent osteoporosis cost-effectiveness modeling literature and provide an overview of their methodologies and approaches. METHODS: A detailed systematic review was performed of the following literature databases: MEDLINE, MEDLINE In-Process, EMBASE, Cochrane, HEED, NHSEED, EconLit, and googlescholar. Using pre-selected inclusion/exclusion criteria relevant studies published since January 2005 were identified. Relevant information from each identified study was extracted according to a predefined grid and essential features of each osteoporosis cost-effectiveness model were recorded. RESULTS: Forty-eight relevant and recently published osteoporosis cost-effectiveness models were identified. Model structures were cohort Markov (56%) and individualized microsimulations (44%). Most models (35) used a lifetime timeframe (i.e., death or Ն age 100). The primary interventions investigated were bisphosphonates (79%), raloxefine (15%), and hormone replacement therapy (10%). In 98% of the models hip fracture was a specific outcome, 94% contained vertebral fractures, and 77% contained wrist/forearm fractures. Eleven models incorporate at least one extraskeletal effect on cost and survival (including breast cancer, coronary heart disease, venous thromboembolism, stroke, and colorectal cancer). Thirty-two (32) of the 48 publications (67%) assume 100% compliance or do not directly mention/ model compliance. The majority of the models take the approach that there was discontinuation and non-compliance in the clinical trials, and that the treatment efficacy rates sourced from the clinical trials are underestimated due to the use of an intention-to-treat paradigm. CONCLUSIONS: The current state of osteoporosis modeling favors a non-cohort Markov approach, with individualized, i.e., microsimulation methodology being increasingly utilized as extraskeletal effects are incorporated. Treatment compliance and extraskeletal effects are extremely important in modeling real-world scenarios, yet they are not incorporated into the majority of the published models. Modeled treatment effectiveness should be properly imputed to account for the intention-to-treat impact of RCT-reported values as well as the reduced benefits of treatment noncompliance. 
PMS27 A COST-EFFECTIVENESS ANALYSIS FROM AN INSTITUTIONAL PERSPECTIVE TO COMPARE ZOLEDRONIC ACID WITH STANDARD OF CARE IN THE PREVENTION OF HIP FRACTURES IN PATIENTS WITH OSTEOPOROSIS
OBJECTIVES:
Because of its prevalent condition and its association with hip fractures in the elderly population, Osteoporosis has become a major concern for health authorities in recent years. The objective of this study is to evaluate the most cost-effective alternative for preventing hip fractures in osteoporosis patients in Mexico. METHODS: A cost-effectiveness analysis was performed within an institutional setting (Mexican Institute of Social Security, IMSS). Patients were categorized into 2 groups by age: group A was comprised with patients ages 60 to 79 years, and group B was comprised with patients aged Ͼ80 years. The standard of care comparator used was all biphosphonates available in the National Formulary: risedronate, original alendronate, generic alendronate, and ibandronate. Resource use data was obtained from published studies; total direct costs of osteoporosis and hip fractures were used. The source of the unit costs was the institution, current for 2006. All costs are expressed in local currency (Mexican Pesos, MXP). The time horizon was 10 years; a discount rate of 3% was used. Effectiveness data was obtained from published studies; the measure used was hip fractures prevented. A probabilistic sensitivity analysis was obtained through a Monte Carlo simulation with 100,000 iterations in the weakest parameters. RESULTS: In both groups, zoledronic acid was the most cost-effective treatment. In group A, the C/E ratio was $221.43 MXP, as compared with $270.77 for generic alendronate, $332.50 for ibandronate, $340.24 for risedronate and $353.32 for original ibandronate. Likewise, in group B the C/E ratio for zoledronic acid was $574.50, as compared to $799.77 for generic alendronate, $941.52 for ibandronate, $961.38 for risedronate, and $993.89 for original alendronate. The sensitivity analysis confirmed the robustness of the model. CONCLUSIONS: From an institutional perspective, zoledronic acid is the most cost-effective alternative for the prevention of hip fractures in patients with osteoporosis in Mexico.
PMS28 COST-EFFECTIVNESS ANALYSIS OF NSAIDS FOR SYMTOMATIC TREATMENT OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS
Tolubaiev V, Zalis'ka O Danylo Halytsky Lviv National Medical University, Lviv, Ukraine OBJECTIVES: High costs of rheumatoid arthritis (RA) and osteoarthritis (OA) due not only to high morbidity, disability and mortality levels, but also basis medications and treatment of adverse events which are very expensive. METHODS: We analyzed the efficacy and safety data from randomized clinical trials and systematic reviews of symptomatic treatment OA and RA patients with meloxicam and diclofenac. We were searching data on: www.cochrane.org, www.pubmed.gov, www.clinicaltrials.gov. A model "decision tree" was built based on two information sources: 1) literature review; 2) cost databases. We calculate the average direct costs of one serious cardiovascular thromboembolic adverse event and one serious gastrointestinal adverse event in Ukraine. We determined the CER based on costs from our "decision tree" model and data from the IMPROVE study. RESULTS: Direct costs of one serious cardiovascular and gastrointestinal adverse event were USD$590.29 and USD$613.81 (1 USD$ ϭ 7.95 UAH on 10.01.2011), respectively. Direct costs of 60 days symptomatic treatment of 100 RA or OA patients with meloxicam 7.5 mg daily and diclofenac 100 mg daily were USD$2057.99 and USD$4975.22, respectively. CER meloxicam was calculated 30.72 and CER diclofenac -117.34. The one-way sensitivity analysis performed with the most relevant varables confirmed this tendency. CONCLUSIONS: Results show that Meloxicam 7.5 daily is more economical effective versus diclofenac 100 mg daily for symptomatic treatment of RA and OA patients taking into account probability of serious cardiovascular tromboembolic and gastrointestinal adverse events. 
PMS29 COST-UTILITY ANALYSIS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, LIMITED FASCIECTOMY, AND PERCUTANEOUS NEEDLE FASCIOTOMY IN DUPUYTREN'S CONTRACTURE
OBJECTIVES:
To assess the cost-effectiveness of limited fasciectomy (LF), percutaneous needle fasciotomy (PNF), and collagenase clostridium histolyticum (CCH) for the treatment of Dupuytren's contracture. METHODS: A Markov model was developed to simulate Dupuytren's contracture progression and estimate clinical/economic implications of LF, PNF, and CCH treatments from a US healthcare payer perspective. Transition probabilities were assumed to follow a beta distribution and were estimated based on results from randomized, clinical trials. Health state utilities and direct costs of therapies were assumed to follow a gamma distribution and obtained from published sources. Half-cycle correction was used with a 1-year cycle length over a 10-year time horizon. One-way sensitivity analyses were performed on relevant variables to test the robustness of the model. Probabilistic sensitivity analysis was performed using 10,000 trial simulations for all variables and results were presented as acceptability curves. The model used a discount rate of 3% per annum and reported in 2010 $US dollars. Primary outcomes evaluated incremental cost-effectiveness ratios. RESULTS: Of the 3 treatment decisions, LF was the dominant strategy. PNF and CCH were estimated to cost an additional $247 and $1844 compared to LF, respectively. An expected difference of Ϫ0.1 and Ϫ0.04 quality-adjusted life years (QALYs) were projected for PNF and CCH relative to LF, respectively. In the one-way sensitivity analysis, the model was sensitive to direct cost of LF with a break-even point of $2000 compared to PNF. The acceptability curve showed that LF had a higher probability of being cost-effective compared to other treatment modalities across a WTP threshold of $0 to $500,000. CONCLUSIONS: Across a WTP threshold between $0 and $500,000, LF was the most cost-effective therapy for the treatment of Dupuytren's contracture compared to PNF and CCH. However, the cost of surgery was sensitive in our model which may vary from site to site. 
PMS30 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL
OBJECTIVES:
To estimate the cost-effectiveness of denosumab vs. the most commonly used therapy (alendronateϩcolecalciferol) in treatment of post-menopausal osteoporosis (PMO) in Portugal. METHODS: A Markov cost-utility life-cycle model with six month cycle length was used. The analysis was undertaken from a National Health Service (NHS) perspective. Efficacy data for denosumab was taken from the FREEDOM randomized double-blind clinical trial and for the comparator from a meta-analysis conducted by NICE. Epidemiological data were derived from Portuguese sources and complemented with Swedish data whenever the former were unavailable. Resource use data were collected through a modified Delphi panel of Portuguese experts (including rheumatologists, GPs and orthopedic surgeons). Resources were valued using various national sources on unit costs. EQ-5D decrements per fracture were based on the international literature. Expected persistence differences between treatments were also considered. Deterministic sensitivity analysis was conducted on key variables (including costs, utilities, impact of fractures on mortality, non-inclusion of sub-optimal persistence, comparator's price, age and T-score for treatment initiation). Probabilistic sensitivity analysis was performed on the model's treatment effects, fracture costs, EQ-5D fracture decrements and persistence rate differences. RESULTS: Considering an annual NHS cost of €382.20 for denosumab, the estimated ICER was €14,487 per QALY gained. The model predicts that, relative to the comparator, denosumab would prevent 12 hip, 22 vertebral, 2 wrist and 1 other osteoporotic fractures, per 1000 patients, over a 10 year period. Deterministic sensitivity analysis identified the absence of a persistence effect and the use of generic alendronate price as the most sensitive parameters (22, 906, 20, 817 €/QALY, respectively) . The probability of costeffectiveness ranged between 91% and 64% (willingness to pay set at 50,000 and 20,000 €/QALY, respectively). CONCLUSIONS: Results from the model suggest that, compared to the most commonly used strategy (alendronateϩcolecalciferol), denosumab is a cost-effective therapy in the treatment of PMO in Portugal. 
PMS31 TITLE: THE RELATIVE COST-EFFECTIVENESS OF THE MOST COMMON NON-SURGICAL TREATMENTS FOR NECK PAIN.
OBJECTIVES:
A major challenge facing policy makers is the lack of economic evidence to guide their decisions about allocating health services for neck pain. Our objective was to evaluate the cost-effectiveness of the most commonly used neck pain treatments in Canada and the United States. METHODS: We conducted a cost-utility analysis with a decision-analytic model of 5 treatments for neck pain (exercise, cyclooxegenase-2 selective inhibitors, manipulation, mobilization, and nonsteroidal anti-inflammatory drugs [NSAIDs]) using a lifetime time horizon and adopting a health care system perspective. Model inputs included: estimates of the course of neck pain; background risk of adverse events in the general population; treatment effectiveness and risk of cerebrovascular, cardiovascular, and gastrointestinal adverse events; quality-of-life weights elicited from neck pain patients using the standard gamble; and direct and out-of-pocket costs. Costs were expressed in 2008 Canadian prices. The impact of beneficial and harmful treatment effects on health were expressed in quality-adjusted life years (QALYs). Cost-effectiveness was estimated with the incremental cost-effectiveness ratio (ICER). The probability that a given treatment was cost-effective was determined using a willingness-to-pay (WTP) threshold of $50,000 per QALY. RESULTS: Under a conven-A128 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
